| 產(chǎn)品編號 | bs-0298R-HRP |
| 英文名稱1 | Rabbit Anti-IGBP1/HRP Conjugated antibody |
| 中文名稱 | 辣根過氧化物酶標(biāo)記的免疫球蛋白結(jié)合蛋白-1抗體 |
| 別 名 | Alpha 4; B cell signal transduction molecule alpha 4; B-cell signal transduction molecule alpha 4; bA351K23.1; CD79a binding protein 1; CD79a-binding protein 1; IBP 1; IBP1; IGBP 1; Igbp1; IGBP1_HUMAN; Immunoglobulin (CD79A) binding protein 1; Immunoglobulin binding protein 1; Immunoglobulin-binding protein 1; Protein alpha 4; Protein alpha-4; Protein phosphatase 2A regulatory subunit alpha 4; Renal carcinoma antigen NY REN 16; Renal carcinoma antigen NY-REN-16. |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Rat, (predicted: Human, Mouse, Pig, Cow, Guinea Pig, ) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 44kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Immunoglobulin binding protein 1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The proliferation and differentiation of B cells is dependent upon a B-cell antigen receptor (BCR) complex. Binding of antigens to specific B-cell receptors results in a tyrosine phosphorylation reaction through the BCR complex and leads to multiple signal transduction pathways. [provided by RefSeq, Jul 2008]. Function: Associated to surface IgM-receptor; may be involved in signal transduction. Involved in regulation of the catalytic activity of PP2A, PP4 and PP6 phosphatases catalytic subunits by protecting them from degradative polyubiquitination until they associate with regulatory subunits. Subunit: Associates with PP2A-alpha and PP2A-beta catalytic subunits, and with PP4 and PP6. Interacts with MID1 and MID2. Interacts with Ubiquitin. Subcellular Location: Cytoplasm (Potential). Tissue Specificity: Ubiquitously expressed with highest levels in heart, skeletal muscle and pancreas. Post-translational modifications: Phosphorylated. Monoubiquitination by MID1 triggers calpain-mediated cleavage and switches IGBP1 activity from protective to destructive. DISEASE: Mental retardation, X-linked, syndromic, 28 (MRXS28) [MIM:300472]: A mental retardation syndrome characterized by agenesis of the corpus callosum, coloboma of the iris and optic nerve, severe retrognathia, and intellectual deficit. Mental retardation is defined by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the IGBP1/TAP42 family. Contains 1 UIM (ubiquitin-interacting motif) repeat. Database links: Entrez Gene: 3476 Human Entrez Gene: 18518 Mouse Omim: 300139 Human SwissProt: P78318 Human SwissProt: Q61249 Mouse Unigene: 496267 Human Unigene: 7454 Mouse Unigene: 7079 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CD79a表達(dá)于從前B細(xì)胞到漿細(xì)胞的整個B細(xì)胞發(fā)育階段。 CD79a與CD79b構(gòu)成B細(xì)胞受體復(fù)合體，在介導(dǎo)IgM從細(xì)胞內(nèi)轉(zhuǎn)到細(xì)胞膜上起重要作用。CD79a是B細(xì)胞常用標(biāo)記物。CD79復(fù)合物是異二聚體分子，由CD79a/mb-1和CD79b/B29 組成。在B細(xì)胞表面非共價(jià)地與膜結(jié)合的免疫球蛋白相連，構(gòu)成B細(xì)胞抗原受體。在大多數(shù)前B細(xì)胞急性淋巴細(xì)胞白血病、B細(xì)胞系、B細(xì)胞淋巴瘤和和某些骨髓瘤中發(fā)現(xiàn)有CD79a的存在。主要用于B淋巴細(xì)胞的判斷和B細(xì)胞淋巴瘤的診斷。 |
